Navigation

Press releases

The NICE press team issues press releases on all published Clinical Guidelines, Technology Appraisals, and Public Health guidance, as well as for consultations on draft guidance and other news from NICE. Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please send an email to pressoffice@nice.org.uk or call the press team on 0845 003 7782.

Results 21-30 of 859

NICE says yes to new treatment for rare autoimmune disease in final guidance
NICE has today published final guidance recommending rituximab (MabThera, Roche Products) as an option for inducing remission in adults with the rare autoimmune condition anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
March 26, 2014

NICE issues final guidance aflibercept for colorectal cancer
NICE, the healthcare guidance body, has issued final guidance that does not recommend aflibercept (Zaltrap, Sanofi) for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen.              
March 25, 2014

NICE guidance supports new device for managing wounds
New NICE medical technology guidance supports a device that aims to help improve the treatment of wounds.
March 25, 2014

NICE unable to give the go ahead to new prostate cancer drug in preliminary recommendations
NICE, the healthcare guidance body, has issued new draft guidance not recommending radium-223 dichloride (Xofigo, Bayer), for treating adults with hormone relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases.
March 24, 2014

NICE consults on draft standards to keep adult patients on drips safe from harm
This will appear on the newsroom homepage and in the RSS feed description: The National Institute for Health and Care Excellence (NICE) has published a set of draft standards to help the NHS ?raise its game? and ensure adults who need fluids through a drip (intravenous fluid therapy) get the safest possible care.
March 21, 2014

NICE proposes to recommend another treatment for multiple myeloma
This will appear on the newsroom homepage and in the RSS feed description.In new draft guidance published today (21 March), NICE has recommended bortezomib (Velcade) as a treatment for some patients with newly diagnosed multiple myeloma.
March 21, 2014

NICE draft guidance recommends new treatment for lung cancer
NICE, the healthcare guidance body, has issued new draft guidance recommending afatinib (also known as Giotrif and made by Boehringer Ingelheim) as an option, for treating locally advanced or metastatic non-small-cell lung cancer in people whose tumours test positive for the EGFR-TK mutation and have not received a EGFR-TK inhibitor.
March 17, 2014

NICE publishes guideline on managing medicines in care homes
NICE has published its guideline about the systems and processes that need to be in place to ensure the safe and effective use of medicines for all children, young people and adults who live in care homes, including those who need nursing care.
March 14, 2014

NICE: Better information needed on multiple myeloma drug
NICE, the healthcare guidance body, has issued new draft guidance on the use of lenalidomide (Revlimid, Celgene) for treating the blood cancer multiple myeloma after one prior treatment with bortezomib. With the current information available, the committee?s preliminary guidance (now being issued for consultation) does not recommend lenalidomide for this indication
March 14, 2014

Hoax email claiming to be from NICE
Hoax email claiming to be from NICE
March 13, 2014

This page was last updated: 23 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.